Combination therapy for relapsed Hodgkin lymphoma without transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two oral targeted drugs (chidamide and decitabine) plus an immunotherapy drug (anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has not responded to at least two prior treatments and who cannot or choose not to have a stem cell transplant. The goal is to see if this three-drug combination can shrink tumors and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old
- You need to have classical Hodgkin lymphoma that has come back or not responded after at least two prior treatments
- You are not able to have a stem cell transplant, or you have chosen not to have one
- You should have a tumor that can be measured on a scan (at least 1 cm in size)
- You must be in generally good health (able to do day-to-day activities) and have adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (chidamide, decitabine, and an immunotherapy drug called an anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has come back or not responded to at least two previous treatments. It may be an option if you cannot have or do not want a stem cell transplant.
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial tests a new combination of two immunotherapy drugs (IMM01 and tislelizumab) compared with standard chemotherapy for people with classical Hodgkin lymphoma that has not responded to PD-1/PD-L1 inhibitors. The goal is to see if this new approach can help when other treatments have failed.
Hear when a new Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.